Mpox in Africa prompts $500 million funding from Gavi for vaccines
Adds DRC government comments in paragraphs 15-16
By Jennifer Rigby
LONDON, Aug 15 (Reuters) -The global vaccine group Gavi has up to $500 million to spend on getting shots to countries affected by an escalating mpox outbreak in Africa, its chief executive Sania Nishtar told Reuters.
Gavi helps countries with fewer resources buy and deploy vaccines, usually against childhood diseases like measles, but it expanded into broader efforts during the COVID-19 pandemic.
The money is available in the organization’s "First Response" fund, which was set up after global health agencies like Gavi were left behind by high-income countries in procuring vaccines during the early days of COVID.
It can be used to respond to health emergencies, which were declared by the World Health Organization and the Africa Centres for Disease Control and Prevention (CDC) this week.
The funds are largely left over from money donated by governments and global health funders for the COVID response.
“The money for the vaccines is ready to be tapped into,” said Nishtar, but there were hurdles to clear, including official requests for vaccines from affected countries, as well as approvals of the vaccines from the World Health Organization, which declared mpox a global health emergency on Wednesday.
Gavi and UNICEF, which work together to buy vaccines, cannot do so without WHO approving them. On Wednesday, the global health agency said it was hoping to finalise its evaluation of the vaccines by September.
Nishtar said Gavi was also in early talks with the manufacturers of the two mpox vaccines that are widely used, made by Bavarian Nordic BAVA.CO and KM Biologics. Official orders can only proceed after approval, she said.
Bavarian Nordic has said it can make 10 million doses by the end of 2025.
"We have already significant capacity in place and can easily handle delivery of all doses needed for the outbreak," a Bavarian Nordic spokesperson said by email.
"But we need someone to buy the doses. None of the organizations have shown interest so far," he added, without providing details.
KM Biologics said in an email it would cooperate with WHO as much as possible.
In the meantime, Gavi is coordinating with countries like the United States, which has had 50,000 doses available for donation for months. Bavarian Nordic has also donated 15,000 doses.
However, the Democratic Republic of Congo, which has been severely affected by the outbreak, has yet to make an official request for the shots, which Nishtar said was a delaying factor, along with arranging legal processes and deployment plans for vaccination.
In a press conference on Thursday, Congo's health minister Samuel Roger Kamba Mulamba said the country needs 3 million vaccine doses.
"That's why it was important to wake up the international community," he said.
Reporting by Jennifer Rigby in London and Ange Adihe Kasongo in Kinshasa; Editing by Bernadette Baum and Jonathan Oatis
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
